Nuclear Medicine AtlasInteractive atlas

Abbreviations & Glossary

A quick-reference key to the acronyms used across nuclear medicine

#reference#glossary#qualityUpdated 2026-07-27 · Physician-reviewed
High-yield mode — key points, high-yield facts, tables & quizzes only. Toggle off for full text.

Quick Answer

A consolidated key to the abbreviations and core terms used throughout the atlas — grouped by domain. Where a term has a dedicated page, the relevant chapter goes deeper; this page is for fast disambiguation.

Physics, Instrumentation & Quantitation

  • ALARA — As Low As Reasonably Achievable
  • AC / SC — Attenuation Correction / Scatter Correction
  • CZT — Cadmium-Zinc-Telluride (solid-state detector)
  • EARL — EANM Research Ltd (SUV harmonization/accreditation)
  • FBP / OSEM — Filtered Back-Projection / Ordered-Subset Expectation Maximization
  • FWHM — Full-Width at Half-Maximum (resolution)
  • LAFOV — Long-Axial-Field-of-View (total-body PET)
  • LEHR / ME / HE — Low-Energy High-Resolution / Medium-Energy / High-Energy (collimator)
  • LET — Linear Energy Transfer
  • MIP — Maximum-Intensity Projection
  • PSF / TOF — Point-Spread-Function modelling / Time-Of-Flight
  • SiPM — Silicon Photomultiplier (digital PET)
  • SPECT / PET — Single-Photon-Emission CT / Positron-Emission Tomography
  • SUV / SUL / SUVpeak — Standardized Uptake Value / lean-body-mass-normalized / peak
  • TEDE — Total Effective Dose Equivalent

Dosimetry, Safety & Regulatory

  • AU / RSO — Authorized User / Radiation Safety Officer
  • BED — Biologically Effective Dose
  • DIS — Decay-In-Storage
  • Gy / Sv — Gray (absorbed dose) / Sievert (equivalent/effective dose)
  • LNT — Linear No-Threshold (stochastic-risk model)
  • MIRD — Medical Internal Radiation Dose (schema; D = Ã × S)
  • NRC — Nuclear Regulatory Commission
  • Ã / τ — Cumulated activity / Residence time
  • T½ (phys/biol/eff) — physical / biological / effective half-life

Cardiac

  • CFR / MFR — Coronary / Myocardial Flow Reserve
  • CTRCD — Cancer-Therapy-Related Cardiac Dysfunction
  • ERNA / MUGA — Equilibrium Radionuclide Angiography / Multigated Acquisition
  • H/M ratio — Heart-to-Mediastinum ratio (I-123-MIBG)
  • LVEF / EDV / ESV — LV Ejection Fraction / End-Diastolic / End-Systolic Volume
  • MBF — Myocardial Blood Flow
  • MPI — Myocardial Perfusion Imaging
  • SSS / SRS / SDS — Summed Stress / Rest / Difference Score
  • TID — Transient Ischemic Dilation

Oncology, Theranostics & Reporting

  • CUP — Carcinoma of Unknown Primary
  • Deauville — 5-point lymphoma metabolic-response scale
  • GEP-NET — Gastroenteropancreatic Neuroendocrine Tumor
  • mCRPC — metastatic Castration-Resistant Prostate Cancer
  • PERCIST / RECIST — PET Response Criteria / Response Evaluation Criteria In Solid Tumors
  • PRRT — Peptide Receptor Radionuclide Therapy
  • PROMISE / PSMA-RADS — PSMA reporting frameworks (miTNM / lesion certainty)
  • RECIP 1.0 — Response Evaluation Criteria In PSMA PET/CT
  • RLT / RPT / TAT — Radioligand / Radiopharmaceutical Therapy / Targeted Alpha Therapy
  • SIRT / TARE — Selective Internal Radiation Therapy / Trans-Arterial RadioEmbolization
  • SSTR — Somatostatin Receptor
  • Krenning — SSTR-uptake grade (0–4; 3–4 → PRRT)

Tracers & Targets (selected)

  • DOTATATE — DOTA-octreotate (SSTR2 PET)
  • FAPI — Fibroblast-Activation-Protein Inhibitor
  • FDG — Fluorodeoxyglucose
  • FDOPA — Fluoro-DOPA (amino-acid/catecholamine)
  • FES — Fluoroestradiol (ER)
  • FLT / FMISO / FAZA — Fluorothymidine (proliferation) / hypoxia nitroimidazoles
  • MAA — Macroaggregated Albumin (perfusion; Y-90 mapping)
  • MAG3 / DTPA / DMSA — renal tubular / glomerular / cortical agents
  • MDP / HDP — diphosphonate bone agents
  • MIBG — Meta-Iodo-Benzyl-Guanidine (NET/uptake-1)
  • NaF — Sodium Fluoride (bone PET)
  • PSMA — Prostate-Specific Membrane Antigen
  • RBC / SC — labeled Red Blood Cells / Sulfur Colloid

Endocrine, Renal & Other

  • DTC / MTC — Differentiated / Medullary Thyroid Carcinoma
  • GBEF — Gallbladder Ejection Fraction (CCK-HIDA)
  • GFR / ERPF — Glomerular Filtration Rate / Effective Renal Plasma Flow
  • MEN — Multiple Endocrine Neoplasia
  • NIS — Sodium-Iodide Symporter
  • RAI / RAIU — Radioactive Iodine / RAI Uptake
  • rhTSH — recombinant human TSH (Thyrogen)
  • VUR — Vesicoureteral Reflux

Board Pearls

Learn the quantitation and scoring acronyms cold — SUV/SUL, MBF/MFR, SSS/SRS/SDS, TID, Krenning, Deauville, PERCIST/RECIST, RECIP — because reporting is expressed in them, and a score communicates management where a description does not.

Keep the therapy family straight: RLT/RPT (radioligand/radiopharmaceutical therapy), PRRT (SSTR peptide), TAT (alpha), SIRT/TARE (Y-90 liver) — each with distinct targets, isotopes, and organs at risk.

  • Reporting: Structured reporting & standardized systems; synthesis: Radiopharmaceutical targets & mechanisms, thresholds & decision cutoffs.

Self-Check

Q1. Expand SSS, SRS, and SDS — and state which is the ischemia number.

Answer: Summed Stress / Rest / Difference Score; SDS (= SSS − SRS) is the reversible/ischemia number.

Q2. What do PRRT, TAT, and SIRT/TARE each denote?

Answer: PRRT = Peptide Receptor Radionuclide Therapy (SSTR); TAT = Targeted Alpha Therapy; SIRT/TARE = Selective Internal Radiation Therapy / Trans-Arterial RadioEmbolization (Y-90 liver).

Q3. Define NIS and rhTSH and where they matter.

Answer: NIS = Sodium-Iodide Symporter (thyroid iodine trapping); rhTSH = recombinant human TSH (Thyrogen), used to stimulate uptake for thyroid-cancer RAI/scanning.

Q4. What does the Krenning score grade, and what value indicates PRRT suitability?

Answer: Somatostatin-receptor uptake (0–4) against reference organs; 3–4 (uptake ≥ liver) indicates PRRT suitability.

Evidence & sources

INFERENCEReference glossary compiled from the atlas's own usage; terms are defined per standard nuclear-medicine nomenclature.
Cite this page. Nuclear Medicine Atlas. “Abbreviations & Glossary.” v1.76, 2026-10-25. Permalink: https://nuc.med/abbreviations-glossary/ Report an issue
Nuclear Medicine Atlas · v1.76 · built 2026-10-25Terms · Privacy · Disclaimer